EUVIMEDEUVIMED entdecken
Crossref

Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy

Rang Wang, Mingxing Huang, Weichen Wang, Mufeng Li, Yingwei Wang, Rong Tian

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.124.268689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Rang Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Lutetium, Serine Endopeptidases, Gelatinases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN.

Methods

FAP-HXN was synthesized and characterized for selectivity and specificity toward FAP. Cellular uptake of the radiolabeled FAP-HXN in human embryonic kidney (HEK)-293-FAP cells with high expressions of FAP was evaluated. The diagnostic and therapeutic potential of 68Ga- and 177Lu-labeled radioligands was evaluated in HEK-293-FAP tumor-bearing mice compared with the FAP-targeting peptide FAP-2286.

Results

FAP-HXN demonstrated high binding ability to human and mouse sources of FAP. Moreover, the in vivo studies confirmed the high affinity and specificity of radiolabeled FAP-HXN. Small-animal PET imaging demonstrated that [68Ga]Ga-FAP-HXN had continuous tumor uptake in FAP-positive tumors after administration compared with [68Ga]Ga-FAP-2286. In the therapeutic experiments, [177Lu]Lu-FAP-HXN showed significant antitumor activity in HEK-293-FAP xenografts at well-tolerated doses, which also exhibited longer tumor retention and better tumor growth inhibition compared with [177Lu]Lu-FAP-2286.

Conclusion

The preclinical studies revealed that radiolabeled FAP-HXN had high tumor uptake, prolonged retention, and significant anticancer efficacy in HEK-293-FAP xenografts. FAP-HXN shows promising potential as a novel theranostic radioligand for FAP-positive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsLutetiumSerine EndopeptidasesGelatinasesMembrane ProteinsPeptidesNeoplasmsHumansAnimalsMiceHEK293 CellsGallium RadioisotopesRadioisotopesEndopeptidasesTissue DistributionCell Line, TumorPositron-Emission TomographyFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

FAPcancer-associated fibroblastspeptideradiopharmaceuticaltheranostic

Substanzen

RadiopharmaceuticalsLutetiumSerine EndopeptidasesGelatinasesGallium RadioisotopesMembrane ProteinsRadioisotopesEndopeptidasesPeptidesFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China rongtiannuclear@126.com.

Zitieren

APA

Wang, R., Huang, M., Wang, W., Li, M., Wang, Y., & Tian, R. (2025). Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268689

Vancouver

Wang R, Huang M, Wang W, Li M, Wang Y, Tian R. Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268689

BibTeX
@article{Wang2025,
  author = {Wang, Rang and Huang, Mingxing and Wang, Weichen and Li, Mufeng and Wang, Yingwei and Tian, Rong},
  title = {Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.124.268689}
}
Kostenlos starten →